WAVE Life Sciences (NASDAQ:WVE) Sets New 52-Week Low – Time to Sell?

WAVE Life Sciences Ltd. (NASDAQ:WVE)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $5.11 and last traded at $5.2590, with a volume of 11044062 shares. The stock had previously closed at $12.30.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company reports positive interim Phase 1 INLIGHT data: Wave said a single 240 mg dose of WVE-007 produced clinically meaningful, placebo‑adjusted reductions in visceral fat and waist circumference at six months — data the company framed as supportive of the program. Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT
• Positive Sentiment: Analyst support: Mizuho raised its price target to $27 and kept an “outperform” rating, and Truist upgraded WVE to a “strong‑buy” — these institutional endorsements suggest upside from current depressed levels if clinical programs recover traction. Mizuho raises price target
• Neutral Sentiment: Broader coverage and Q4 commentary: multiple analyst notes and investor‑letter mentions (including coverage in The Globe and Mail and Q4 writeups) highlight improving fundamentals for small‑cap biotech names but offer limited immediate clarity on INLIGHT’s commercial prospects. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Options/volume activity flagged: reports of unusually high options trading and very elevated volume preceded the move, indicating positioning and volatility that can amplify swings but not change fundamentals alone. WAVE Life Sciences Target of Unusually High Options Trading
• Negative Sentiment: Market reaction to high‑dose data disappointment: Reuters and multiple outlets reported that a higher WVE-007 dose failed to show a clear improvement in reducing visceral (dangerous belly) fat, which triggered a steep intraday selloff and heavy volume as investors re‑priced the program’s near‑term prospects. Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints
• Negative Sentiment: Shareholder investigation announced: Johnson Fistel said it is investigating potential claims against Wave executives related to investor losses, which increases legal/PR risk and can prolong volatility and selling pressure. WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel

Analysts Set New Price Targets

WVE has been the subject of a number of recent research reports. UBS Group set a $32.00 target price on WAVE Life Sciences in a report on Tuesday, December 16th. Citigroup lifted their price target on WAVE Life Sciences from $16.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Canaccord Genuity Group boosted their price target on WAVE Life Sciences from $43.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Cantor Fitzgerald upped their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Royal Bank Of Canada upgraded shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $9.00 to $27.00 in a report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.31.

WAVE Life Sciences Price Performance

The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -4.63 and a beta of -1.77. The stock has a fifty day moving average of $13.24 and a two-hundred day moving average of $11.24.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%.The company had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. On average, research analysts forecast that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 3,588 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $48,258.60. Following the sale, the chief financial officer directly owned 134,385 shares in the company, valued at $1,807,478.25. This represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Paul Bolno sold 10,480 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $140,956.00. Following the sale, the chief executive officer directly owned 275,520 shares of the company’s stock, valued at $3,705,744. This represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 61,748 shares of company stock valued at $907,809 in the last ninety days. Insiders own 23.98% of the company’s stock.

Hedge Funds Weigh In On WAVE Life Sciences

A number of hedge funds have recently bought and sold shares of the company. CWM LLC boosted its position in WAVE Life Sciences by 6,729.0% during the fourth quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after acquiring an additional 2,086 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after purchasing an additional 1,942 shares during the period. Bessemer Group Inc. boosted its position in shares of WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after purchasing an additional 9,135 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock valued at $73,000 after purchasing an additional 9,284 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in WAVE Life Sciences by 18.7% during the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after purchasing an additional 1,802 shares during the period. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.